PCSK9 base editing
InterventionPreclinical
1 paper2 findings
Outcomes
2Circulating PCSK9
downin reviews1
1 study
Circulating PCSK9
downin reviews1
PCSK9 base editing decreases circulating PCSK9.
“Preliminary interim and preclinical data suggest that this strategy is effective for long-term reduction of PCSK9 and LDL-C following a single IV infusion.”
Reviewpreliminary interim and preclinical datapackaged within lipid nanoparticlessingle IV infusion
In-vivo CRISPR/Base-Editing "One-Shot" Therapies Targeting PCSK9
Current atherosclerosis reportsOct 15, 2026
LDL-C
downin reviews1
1 study
LDL-C
downin reviews1
PCSK9 base editing decreases LDL-C.
“Preliminary interim and preclinical data suggest that this strategy is effective for long-term reduction of PCSK9 and LDL-C following a single IV infusion.”
Reviewpreliminary interim and preclinical datapackaged within lipid nanoparticlessingle IV infusion
In-vivo CRISPR/Base-Editing "One-Shot" Therapies Targeting PCSK9
Current atherosclerosis reportsOct 15, 2026
Latest
1 in 12 monthsCurrent Atherosclerosis Reports
In-vivo CRISPR/Base-Editing "One-Shot" Therapies Targeting PCSK9
ReviewInterventions